what is microdosing of glp-1 GLP-1: A Next-Generation Approach to Metabolic and Longevity Medicine: Shamsah Amersi, MD: OB-GYNs One Size Does Not Fit

Its also in Phase 3 trials and not yet FDA approved

A 2022 meta-analysis of 37 RCTs involving 3,048 patients, published in Frontiers in Pharmacology , found that berberine significantly reduced fasting plasma glucose by an average of 0.82 mmol/L and HbA1c by 0.63% without significantly increasing hypoglycemia risk

These are the manufacturer or retail cash prices many patients see before discounts or savings programs

Its current profile is based on ongoing clinical trials conducted by its manufacturer and research collaborators

Schffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI

10.1007/s00213-018-4992-7 39